Clonal selection of CD56+ t(8;21) AML blasts: further suggestion of the adverse clinical significance of this biological marker?
Article first published online: 24 DEC 2001
British Journal of Haematology
Volume 107, Issue 2, pages 381–383, November 1999
How to Cite
Daniels, J. T., Davis, B. J., Houde-McGrail, L. and Byrd, J. C. (1999), Clonal selection of CD56+ t(8;21) AML blasts: further suggestion of the adverse clinical significance of this biological marker?. British Journal of Haematology, 107: 381–383. doi: 10.1046/j.1365-2141.1999.01711.x
- Issue published online: 24 DEC 2001
- Article first published online: 24 DEC 2001
- neural cell adhesion molecule;
- acute mylogenous leukaemia;
- clonal selection;
- chromosomal translocation
Although patients with acute myelogenous leukaemia (AML) and t(8;21)(q22;q22) have a favourable prognosis, a subset die despite receiving appropriate treatment. Recent reports suggest that expression of the CD56 antigen might predict for both extramedullary disease and poor outcome in these patients. We describe a patient who presented with CD56-negative t(8;21) AML who achieved a complete remission and was subsequently treated with three consolidative courses of high-dose cytarabine therapy. She relapsed 9 months later with extramedullary and bone marrow involvement of CD56-positive t(8;21) AML. This case demonstrates clonal evolution and provides further support that blast expression of CD56 might be an unfavourable prognostic factor in t(8;21) AML.